Difficulty: Medium
Average Score: 77%
Practice
An elderly man with COPD is being managed with several drugs, one of which is inhaled ipratropium. Which of the following is the main mechanism that accounts for the beneficial effects of this drug?
Correct answer
A
Rationale
The correct answer is A) Blocks of an endogenous bronchoconstrictor mediator.
Explanation:
Ipratropium is an anticholinergic medication that works by blocking acetylcholine receptors in the airways. Acetylcholine normally causes bronchoconstriction, so by blocking its action, ipratropium helps dilate the airways, making it easier for the patient to breathe. This mechanism is especially beneficial for patients with COPD who often have narrowed airways due to inflammation and mucus production.
Why others are wrong:
B) Inhibiting cAMP breakdown via phosphodiesterase inhibition is the mechanism of action for medications like theophylline, not ipratropium.
C) Preventing antigen-antibody reactions that lead to mast cell mediator release is the mechanism of action for mast cell stabilizers like cromolyn sodium, not ipratropium.
D) Stimulating ventilatory rates (CNS effect in brain's medulla) is not the mechanism of action for ipratropium. It does not have a direct central nervous system effect to increase ventilatory rates.
Educational context:
Understanding the mechanism of action of drugs used to manage respiratory conditions is crucial for healthcare professionals to make informed decisions about treatment options for patients. Knowing how ipratropium works helps in optimizing therapy for patients with COPD and other respiratory conditions. It also highlights the importance of personalized medicine and tailoring treatment to individual patient needs.
Explanation:
Ipratropium is an anticholinergic medication that works by blocking acetylcholine receptors in the airways. Acetylcholine normally causes bronchoconstriction, so by blocking its action, ipratropium helps dilate the airways, making it easier for the patient to breathe. This mechanism is especially beneficial for patients with COPD who often have narrowed airways due to inflammation and mucus production.
Why others are wrong:
B) Inhibiting cAMP breakdown via phosphodiesterase inhibition is the mechanism of action for medications like theophylline, not ipratropium.
C) Preventing antigen-antibody reactions that lead to mast cell mediator release is the mechanism of action for mast cell stabilizers like cromolyn sodium, not ipratropium.
D) Stimulating ventilatory rates (CNS effect in brain's medulla) is not the mechanism of action for ipratropium. It does not have a direct central nervous system effect to increase ventilatory rates.
Educational context:
Understanding the mechanism of action of drugs used to manage respiratory conditions is crucial for healthcare professionals to make informed decisions about treatment options for patients. Knowing how ipratropium works helps in optimizing therapy for patients with COPD and other respiratory conditions. It also highlights the importance of personalized medicine and tailoring treatment to individual patient needs.